BioSpace News Archive

DataPath, Inc., a leading developer of technology solutions for employer-sponsored benefits, announced today that it has released new materials for its award-winning The Adventures of Captain Contributor™ education and engagement program

The global addictions therapeutics market is expected to post a CAGR of over 5% during the period 2019-2023, according to the latest market research report by Technavio.

BioSurfaces, Inc. (BioSurfaces) was awarded a contract from the National Center for Advancing Translational Sciences (NCATS) BioPrinting Lab at the National Institutes of Health to produce 96-well tissue culture plate assemblies that include its proprietary electrospun materials.

AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today the appointment of Naofumi Kagami as Site Head/General Manager of the Chiba, Japan facility.

A new Cohen Clinic offering accessible, high-quality mental healthcare will open in the Last Frontier in early 2020

Hard Rock International continues its support for PINKTOBER® as the brand celebrates two decades of its annual PINKTOBER campaign, supporting breast cancer awareness and research.

Empirical Spine, Inc., a Silicon-Valley based medical technology company, announced today that data from the IDE study of the company’s LimiFlex Paraspinous Tension Band for patients suffering from degenerative spondylolisthesis with lumbar spinal stenosis, will be presented at the Society for Minimally Invasive Spine Surgery (SMISS) Annual Forum 2019.

As major drug makers from Johnson & Johnson to Purdue Pharma face mounting legal challenges for their role in the US opioid epidemic, suppliers of the $94 billion global pharmaceutical packaging industry are using innovation to comply with regulations aimed at preventing such crises in the future.

AHF Echoes MSF Call on WHO for Increased Ebola Vaccine in DRC, Greater Transparency

Amgen (NASDAQ:AMGN) today announced that the results of a prespecified interim analysis of an open-label, randomized, controlled global multicenter Phase 3 trial (20120215) showed that the primary endpoint of event-free survival was met.